CSI Market
Sign In | Register

Bellerophon Therapeutics inc (BLPH) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access BLPH Annual Cash Flow →
This cash flow overview for Bellerophon Therapeutics inc spans from Sep 30 2022 to Sep 30 2023, illustrating how cash generation and usage have shifted across recent reporting periods.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-4.24
Depreciation & amortization0.00
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment-0.14
Share-based Compensation0.42
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Increase Decrease In Restricted Cash Held For Ikaria Inc.-
Increase Decrease In Restricted Cash Held As Security Deposit-
Debt Issuance Costs-
Debt Related Commitment Fees And Debt Issuance Costs-
Increase Decrease In Accounts Payable Accrued Research And Development And Other Liabilities-3.96
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Due from Related Parties, Current, Total0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.00
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-0.26
Other Working Capital0.19
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-7.99
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.14
Proceeds from Sale and Maturity of Marketable Securities0.00
Payments to Acquire Marketable Securities0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.14
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.03
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock3.55
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Cash Contribution By Former Parent In Connection With Spin Out-
Cash Contributions By Former Parent To Fund Operations-
Proceeds From Issuance Initial Public Offering Net Of Issuance Costs-
Proceeds from Issuance of Common Stock Net-
Proceeds from Issuance of Common Stock and Warrants Net-
Payments Of Transaction Costs-
Proceeds From Issuance Of Common Stock Net1.44
Proceeds From Warrant Exercises Pending Issuance Of Common Shares-
Proceeds Secondary Offering-
Proceeds from Issuance of Common Stock and Warrants Net P I P E Offering-
Proceeds from Issuance of Common Stock and Warrants Net Direct Offering-
Warrants Exercised Fair Value-
Fair Value Reclassification Of Warrant Liability-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities5.01
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-7.85
Total Cash Flow-2.84
4 historic quarters locked

Sign in to unlock the full Bellerophon Therapeutics inc cash flow history.

Sign In Create Free Account

About Bellerophon Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001558370-23-019044

Figures are derived from filed reports and may be restated. Historical data is subject to revision.